A detailed history of Vanguard Group Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,847,930 shares of JANX stock, worth $104 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,847,930
Previous 1,561,758 18.32%
Holding current value
$104 Million
Previous $65.4 Million 28.32%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$35.29 - $50.26 $10.1 Million - $14.4 Million
286,172 Added 18.32%
1,847,930 $84 Million
Q2 2024

Aug 13, 2024

BUY
$35.12 - $64.78 $7.16 Million - $13.2 Million
203,798 Added 15.01%
1,561,758 $65.4 Million
Q1 2024

May 10, 2024

BUY
$7.93 - $49.75 $3 Million - $18.8 Million
378,477 Added 38.64%
1,357,960 $51.1 Million
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $217,631 - $435,263
37,202 Added 3.95%
979,483 $10.5 Million
Q3 2023

Nov 14, 2023

BUY
$9.56 - $14.0 $1.72 Million - $2.52 Million
180,291 Added 23.66%
942,281 $9.5 Million
Q2 2023

Aug 14, 2023

SELL
$11.08 - $15.92 $118,168 - $169,786
-10,665 Reduced 1.38%
761,990 $9.04 Million
Q1 2023

May 15, 2023

BUY
$11.25 - $22.21 $202,893 - $400,557
18,035 Added 2.39%
772,655 $9.35 Million
Q4 2022

Feb 10, 2023

SELL
$11.1 - $18.26 $64,979 - $106,894
-5,854 Reduced 0.77%
754,620 $9.94 Million
Q3 2022

Nov 14, 2022

BUY
$10.82 - $16.84 $1.2 Million - $1.87 Million
110,834 Added 17.06%
760,474 $10.3 Million
Q2 2022

Aug 12, 2022

BUY
$9.52 - $15.65 $796,452 - $1.31 Million
83,661 Added 14.78%
649,640 $7.93 Million
Q1 2022

May 13, 2022

BUY
$13.24 - $20.24 $435,701 - $666,057
32,908 Added 6.17%
565,979 $8.12 Million
Q4 2021

Feb 14, 2022

BUY
$15.44 - $27.32 $43,679 - $77,288
2,829 Added 0.53%
533,071 $10.5 Million
Q3 2021

Nov 12, 2021

BUY
$20.7 - $34.69 $10.4 Million - $17.4 Million
501,266 Added 1729.94%
530,242 $11.5 Million
Q2 2021

Aug 13, 2021

BUY
$18.58 - $25.37 $538,374 - $735,121
28,976 New
28,976 $723,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.34B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.